Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis

Haemophilia. 2021 Jan;27(1):113-119. doi: 10.1111/hae.14171. Epub 2020 Oct 20.

Abstract

Aims: There is evidence that people with haemophilia A still experience morbidity and functional limitation due to joint damage despite prophylaxis. This study aimed to compare their quality of life and work-related function with that of the general population and patients with osteoarthritis.

Methods: Data from the Cost of Haemophilia in Europe: a Socioeconomic Survey (CHESS) database were compared with published data from normative populations and patients with osteoarthritis in Europe and the United States.

Results: In the predominantly young (age 18-35 years) adult CHESS population treated with primary prophylaxis, about 30% reported a target joint; the average frequency of bleeds was one per year; half reported chronic pain. Levels of anxiety and depression were similar to those reported by people using on-demand treatment. Employment and productivity were lower than in the general population. The level of presenteeism (attending work with impairment) was comparable with that reported for a much older population with osteoarthritis who had more extensive joint damage and greater prevalence of pain.

Conclusion: Compared with the general population, clinical outcomes and quality of life are indicated to be impaired for young adults whose haemophilia is managed by primary prophylaxis. Primary prophylaxis is not associated with lower levels of anxiety and depression than on-demand treatment, and pain is common. The level of presenteeism is comparable to that reported in people with osteoarthritis, an older population with more joint disease. Further studies are needed to fully assess the implications of compromised work performance among young adults with haemophilia as they seek to build a career.

Keywords: Haemophilia A; anxiety; depression; pain; presenteeism; prophylaxis.

MeSH terms

  • Adolescent
  • Adult
  • Cost of Illness
  • Factor VIII
  • Hemophilia A* / complications
  • Hemophilia A* / drug therapy
  • Hemorrhage
  • Humans
  • Quality of Life
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Factor VIII

Grants and funding